Horse Tendon Stem Cell Therapy Advances

Mesenchymal stem cell therapies for equine superficial digital flexor tendon injuries improve healing quality and reduce re-injury rates in performance horses.

Key Facts

Superficial digital flexor tendon injuries affect up to 11% of racehorses and 8% of event horses annually
Conventional healing produces fibrous scar tissue with inferior mechanical properties, leading to 65% re-injury rates
Stem cell therapy promotes more organized collagen fiber formation closer to native tendon structure
Bone marrow-derived and adipose-derived stem cells are both used, with ongoing comparison of efficacy
Platelet-rich plasma (PRP) is often combined with stem cells in modern regenerative protocols

Welfare Considerations

Tendon injuries cause significant pain and extended convalescence, often 12-18 months. Poor healing quality means horses face repeated injury cycles and prolonged suffering. Regenerative therapies that improve tissue quality reduce re-injury risk, shortening the overall welfare burden on affected horses. Ethical considerations include ensuring horses return to appropriate workloads after recovery and that performance pressures do not lead to premature return to work before healing is complete.

What You Can Do

Work with an equine veterinarian experienced in regenerative medicine for tendon injuries
Follow evidence-based rehabilitation protocols including controlled exercise progression
Use ultrasound monitoring to guide return to work decisions objectively
Consider whether performance demands allow adequate recovery time after tendon injury
Support research comparing long-term outcomes of different regenerative approaches